Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALQUENCE vs IMBRUVICA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK activation results in pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib and its active metabolite, acalabrutinib M27, form a covalent bond with the cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity and downstream signaling, thereby reducing malignant B-cell survival and proliferation.
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to irreversible inhibition of BTK activity. BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways, which are involved in the survival, proliferation, and migration of malignant B cells.
FDA-approved: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,FDA-approved: Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),Off-label: Treatment of Waldenström macroglobulinemia,Off-label: Treatment of marginal zone lymphoma
Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy,Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL),Waldenström's macroglobulinemia (WM),Relapsed or refractory marginal zone lymphoma (MZL) in patients who have received at least one prior anti-CD20-based therapy,Chronic graft versus host disease (c GVHD) after failure of one or more lines of systemic therapy,Relapsed or refractory follicular lymphoma (off-label)
100 mg orally twice daily.
560 mg orally once daily for mantle cell lymphoma; 420 mg orally once daily for chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.
Terminal elimination half-life is 8 hours at steady state, supporting twice-daily dosing.
Terminal elimination half-life is approximately 4–6 hours. No clinically relevant accumulation is observed at steady state.
Primarily metabolized by CYP3A4 to form acalabrutinib M27 (active metabolite). Minor routes include glutathione conjugation and hydrolysis. Acalabrutinib is also a substrate of CYP3A5 and to a lesser extent CYP2C8.
Ibrutinib is primarily metabolized by cytochrome P450 (CYP) 3A4, and to a minor extent by CYP2D6. The major active metabolite is PCI-45227, which has similar inhibitory activity against BTK. Avoid coadministration with strong or moderate CYP3A4 inhibitors or inducers.
Fecal (77%), renal (15% as unchanged drug and metabolites).
Primarily via feces (approximately 80% as metabolites and parent drug); renal excretion accounts for <10% of the dose.
97% bound to plasma proteins (albumin and alpha-1 acid glycoprotein).
Approximately 97.3% bound to plasma proteins (primarily albumin).
Approximately 10 L/kg, indicating extensive tissue distribution.
Volume of distribution is approximately 10,000 L (extremely large, indicating extensive tissue distribution, but not typically expressed in L/kg).
Oral bioavailability is approximately 70%; absorption is unaffected by food.
Oral bioavailability is approximately 2.9% (low due to extensive first-pass metabolism and poor absorption; food increases exposure by about 60%).
No dose adjustment required for Cr Cl >=30 m L/min. For Cr Cl <30 m L/min, reduce dose to 100 mg once daily.
No dose adjustment required for GFR ≥ 30 m L/min. For GFR < 30 m L/min, use with caution and monitor closely; no specific dose recommendation available.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 100 mg once daily. Child-Pugh C: avoid use.
Child-Pugh A: 280 mg orally once daily (starting dose for CLL/SLL, WM, MZL, c GVHD) or 420 mg orally once daily (starting dose for MCL). Child-Pugh B: 140 mg orally once daily (CLL/SLL, WM, MZL, c GVHD) or 280 mg orally once daily (MCL). Child-Pugh C: Not recommended.
Not established for pediatric patients.
Not approved for pediatric use. Safety and efficacy not established.
No specific dose adjustment beyond standard monitoring for toxicity.
No specific dose adjustment required; patients ≥65 years experienced higher incidence of certain adverse events (e.g., atrial fibrillation, hypertension) in clinical trials; monitor closely.
None
Hemorrhage: Fatal and serious hemorrhagic events have occurred in patients treated with IMBRUVICA. Major hemorrhage (≥ Grade 3) has occurred in up to 6% of patients. Bleeding events include intracranial hemorrhage, gastrointestinal bleeding, hematuria, and post-procedural hemorrhage. Monitor for signs of bleeding. Consider benefit-risk of surgery and the need for temporary interruption.
Hemorrhage: Fatal and serious bleeding events have occurred. Monitor for signs of bleeding, especially in patients on antithrombotic agents or with thrombocytopenia. Consider benefit-risk of holding acalabrutinib for 3-7 days pre- and post-surgery.,Infections: Fatal and serious infections, including opportunistic infections, have occurred. Monitor for signs and symptoms of infection and treat promptly.,Cytopenias: Grade 3 or 4 cytopenias (neutropenia, anemia, thrombocytopenia) can occur. Monitor complete blood counts regularly.,Second primary malignancies: Including skin cancers and other solid tumors. Advise patients to use sun protection.,Cardiac arrhythmias: Atrial fibrillation and atrial flutter have been reported. Monitor for cardiac arrhythmias and manage appropriately.,Hepatotoxicity: Elevations in liver enzymes have occurred. Monitor liver function tests.,Interstitial lung disease (ILD): Cases of ILD/pneumonitis have occurred. Monitor for pulmonary symptoms and manage as indicated.
Hemorrhage: risk of bleeding, including fatal events; consider withholding for at least 3-7 days pre- and post-surgery,Infections: fatal and serious infections have occurred (e.g., pneumonia, sepsis); monitor for infections,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia may occur; monitor blood counts,Cardiac arrhythmias: atrial fibrillation and ventricular tachyarrhythmias; monitor electrocardiogram and manage as appropriate,Tumor lysis syndrome: risk in patients with high tumor burden; ensure adequate hydration and monitoring,Hypertension: monitor blood pressure and initiate antihypertensive therapy as needed,Second primary malignancies: including skin cancers and other carcinomas,Hepatotoxicity: elevations in liver enzymes; monitor hepatic function,Embryo-fetal toxicity: can cause fetal harm; advise women of reproductive potential to avoid pregnancy
None (no absolute contraindications). Avoid use in patients with severe hepatic impairment (Child-Pugh class C) due to lack of data; use with caution in moderate impairment (Child-Pugh class B).
None
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit (which contain strong CYP3A4 inhibitors) during treatment with CALQUENCE. No other specific food restrictions are required. The drug can be taken with or without food.
Avoid grapefruit, grapefruit juice, Seville oranges, and pomelos. These fruits inhibit CYP3A4 and increase ibrutinib levels, raising toxicity risk (bleeding, arrhythmias). No other significant food interactions.
Based on animal studies and its mechanism of action (Bruton's tyrosine kinase inhibitor), CALQUENCE (acalabrutinib) may cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of acalabrutinib to pregnant rats during organogenesis resulted in embryofetal mortality and malformations at exposures below the clinical exposure at the recommended human dose. There are no adequate and well-controlled studies in pregnant women. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester exposure poses highest risk; second and third trimesters also carry risk of fetal toxicity.
Embryo-fetal toxicity risk. Based on mechanism of action (Bruton's tyrosine kinase inhibitor) and animal studies, there is potential for teratogenicity. Avoid use during pregnancy unless benefit outweighs risk. For first trimester: high risk due to critical organogenesis; second and third trimesters: may cause fetal harm, including low birth weight and developmental abnormalities.
No data are available on the presence of acalabrutinib or its metabolites in human milk, effects on the breastfed child, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with CALQUENCE and for at least 2 weeks after the last dose. M/P ratio is unknown.
No data on presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 1 week after last dose. M/P ratio unknown.
No specific dose adjustments are recommended for pregnancy due to lack of data on pharmacokinetic changes. However, because of potential alterations in drug metabolism and clearance during pregnancy, therapeutic drug monitoring may be considered if available. The manufacturer does not provide guidance for dose adjustment in pregnant women; use during pregnancy should be avoided unless clearly needed.
No specific dose adjustments established. Consider alternative therapy if pregnancy occurs. Systemic exposure may decrease due to increased plasma volume and hepatic metabolism, but no PK data in pregnancy. Do not adjust dose; discontinue if pregnancy occurs unless benefit justifies risk.
CALQUENCE (acalabrutinib) is a selective BTK inhibitor used in B-cell malignancies. It has fewer off-target effects than ibrutinib, particularly less atrial fibrillation and bleeding. Monitor for atrial fibrillation, hypertension, infections (especially respiratory), and bleeding events. Drug interactions with CYP3A4 inducers/inhibitors are significant; avoid concurrent use with strong CYP3A4 inhibitors or inducers. May need to hold for 3 days before and after procedures due to bleeding risk. Consider antiviral prophylaxis for herpes zoster in high-risk patients. Do not crush or break capsules; swallow whole with water. Dose adjustment for severe hepatic impairment (Child-Pugh C) is required.
Monitor for atrial fibrillation (ECG if palpitations), bleeding risk due to antiplatelet effect (hold 3-7 days before surgery), and tumor lysis syndrome (especially CLL with high lymphocytosis). CYP3A4 substrate: avoid strong inhibitors (ketoconazole, clarithromycin) and reduce dose with moderate inhibitors (fluconazole, diltiazem). Check for HBV reactivation before starting.
Take CALQUENCE exactly as prescribed, usually twice daily with or without food. Swallow capsules whole; do not open, break, or chew them.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit while taking this medication, as they can affect how the drug works.,Tell your healthcare provider about all medications you take, including prescription, over-the-counter, vitamins, and herbal products, especially St. John's wort.,CALQUENCE can increase your risk of serious infections, bleeding problems, and heart rhythm issues. Report any signs of infection (fever, chills), unusual bruising or bleeding, palpitations, or dizziness.,Do not stop taking CALQUENCE without consulting your healthcare provider. If you miss a dose, take it as soon as you remember unless it is less than 6 hours until your next dose; then skip the missed dose.,Women who are pregnant or breastfeeding should not take CALQUENCE. Effective contraception is needed during treatment and for 1 week after the last dose.,Keep CALQUENCE in the original container at room temperature (68°F to 77°F), away from moisture and light.
Take with a full glass of water at the same time each day. Swallow capsules whole, do not open, break, or chew.,Do not drink grapefruit juice, Seville oranges, or pomelos while taking this medication.,Report any new or worsening bruising, bleeding, black/tarry stools, or pink/dark urine immediately.,Seek medical attention for symptoms of atrial fibrillation like palpitations, chest discomfort, or shortness of breath.,Avoid activities that increase bleeding risk (e.g., contact sports) until you know how the drug affects you.,Inform all healthcare providers (including dentists) that you are taking ibrutinib before any procedures.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALQUENCE vs IMBRUVICA, answered by our medical review team.
CALQUENCE is a BTK Inhibitor that works by Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK activation results in pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib and its active metabolite, acalabrutinib M27, form a covalent bond with the cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity and downstream signaling, thereby reducing malignant B-cell survival and proliferation.. IMBRUVICA is a BTK Inhibitor that works by Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to irreversible inhibition of BTK activity. BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways, which are involved in the survival, proliferation, and migration of malignant B cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALQUENCE and IMBRUVICA depend on the specific clinical indication. These are both BTK Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALQUENCE is: 100 mg orally twice daily.. The standard adult dose of IMBRUVICA is: 560 mg orally once daily for mantle cell lymphoma; 420 mg orally once daily for chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALQUENCE and IMBRUVICA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALQUENCE is classified as Category C. Based on animal studies and its mechanism of action (Bruton's tyrosine kinase inhibitor), CALQUENCE (acalabrutinib) may cause fetal harm when administered to a pregnant woman. In a. IMBRUVICA is classified as Category C. Embryo-fetal toxicity risk. Based on mechanism of action (Bruton's tyrosine kinase inhibitor) and animal studies, there is potential for teratogenicity. Avoid use during pregnancy . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.